Citation Impact
Citing Papers
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
The Serine Protease TMPRSS6 Is Required to Sense Iron Deficiency
2008 StandoutScienceNobel
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
1999
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
MYC on the Path to Cancer
2012 Standout
A view on drug resistance in cancer
2019 StandoutNature
Are the Major Effects of P-Glycoprotein Modulators Due to Altered Pharmacokinetics of Anticancer Drugs?
1996
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
1988 StandoutNature
The Treatment of Multiple Myeloma
1994
Heart-Rate Recovery Immediately after Exercise as a Predictor of Mortality
1999 Standout
Primary gastrointestinal sarcomas: Analysis of prognostic variables
1995
AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies
2008
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
2004 Standout
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.
1996
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Head and neck cancer
2008 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
Chemotherapy for advanced gastric cancer
2010
Multiple myeloma
2000 Standout
Chemotherapy for advanced gastric cancer
2005
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
1989
Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer
1994
Increased plasma viscosity as a reason for inappropriate erythropoietin formation.
1993 StandoutNobel
High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
1994
Targeting multidrug resistance in cancer
2006 Standout
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Two Hundred Gastrointestinal Stromal Tumors
2000 Standout
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
1990
Immunity, Inflammation, and Cancer
2010 Standout
Malignant Gliomas in Adults
2008 Standout
Infectious and immunosuppressive complications of purine analog therapy.
1995
Hematopoietic Stem-Cell Transplantation
2006 Standout
Treatment of Relapsed/Refractory Multiple Myeloma
2009
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
2003 Standout
Strategies for Inhibition of MDR1 Gene Expression
2004
Head and Neck Cancer
1993 Standout
Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies
1995
Prevalence and outcomes of anemia in cancer: a systematic review of the literature
2004
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
1990 Standout
INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA
1989
Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma
1998
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience
2003
Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer
2000
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.
1989
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma
2000
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
1993 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
The inflammatory reflex
2002 StandoutNature
Doxorubicin-Induced Cardiomyopathy
1998 Standout
Development of Multidrug-Resistance Convertors: Sense or Nonsense?
2000
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
1995
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
1994
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
2002
Anemia of Chronic Disease
2005 Standout
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival
2000
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Cancer of the Ovary
2004 Standout
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914)
2001
TNF-α activates solitary nucleus neurons responsive to gastric distension
2000
The Role of ABC Transporters in Clinical Practice
2003
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium
1985
Cancer of the Breast
1980
Tumour stem cells and drug resistance
2005 Standout
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
1975 Standout
Changing role of chemotherapy in treatment of head and neck cancer
1982
Relative Risk Trees for Censored Survival Data
1992
Head and Neck Cancer
2020 Standout
Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.
1986
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
2010
The Current Status and Future Prospects of Treatment for Multiple Myeloma
1982
Adriamycin in combination for the treatment of breast cancer.A southwest oncology group study
1978
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study [see comments]
1990
Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.
1987
Serum beta2microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.
1983
A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients
1980
Chemotherapy for advanced gastric cancer
2017 Standout
Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial
1978
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study
1996
Drug Treatment of Breast Cancer
1978
Prognostic factors and staging in multiple myeloma: a reappraisal.
1986
The importance of dose intensity in chemotherapy of metastatic breast cancer.
1984 Standout
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
2003 Standout
Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma
1997
ON THE KINETICS OF IRON ABSORPTION IN MICE*
1962
Regulation of apoptosis by the circadian clock through NF-κB signaling
2011 StandoutNobel
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
2002
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma
2002
Adriamycin combinations in advanced breast cancer:A southwest oncology group study
1982
Chimeric Antigen Receptor Therapy
2018 Standout
Criteria of tumor response used in clinical trials of chemotherapy.
1985
T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
2016
p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy
1993
Graphical Methods for Censored Data
1991
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin
1979
Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma
1991
The Anthracycline Antineoplastic Drugs
1981 Standout
Multiple Myeloma
2011 Standout
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study [see comments]
1990
Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
1984
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
1982
Serum β 2-microglobulin in myelomatosis: potential value in stratification and monitoring
1980
International Staging System for Multiple Myeloma
2005 Standout
Works of John D. Bonnet being referenced
A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study
1995
Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.
1988
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
1990
Phase II study of Fludarabine Phosphate in multiple myeloma
1990
Phase II Studies of Recombinant Human Tumor Necrosis Factor Alpha in Patients with Malignant Disease: A Summary of the Southwest Oncology Group Experience
1991
Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus Versus Infusion in Patients With Soft-Tissue Sarcomas: A Southwest Oncology Group Study
1991
Combination therapy for multiple myeloma
1977
cis-Dichlorodiamminepltinum(II) in adult patients: Southwest Oncology Group Studies.
1980
Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma
1983
Combination chemotherapy and adriamycin in patients with advanced breast cancer.A Southwest Oncology Group study
1976
Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
1986
A Quantitative Method for Measuring the Gastrointestinal Absorption of Iron
1960
5FU infusion with mitomycin-C versus 5FU infusion with methyl-CCNU in the treatment of advanced colon cancer.A southwest oncology group study
1978
5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. A Southwest oncology group study
1979
Chemoimmunotherapy for multiple myeloma
1981
Combination chemotherapy for multiple myeloma
1972
Prognostic factors in multiple myeloma
1975
Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.
1983
Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study
1983